Aclarion announces $2.5 million share repurchase program

Written by Emily J. Thompson, Senior Investment Analyst

Source: seekingalpha

Updated: Apr 22 2026

0mins

ACON+4.13%Explore Agentic TradingLet AI Trade for You

Source: seekingalpha

Aclarion Inc's stock price rose by 7.65% after the company announced a share repurchase program of up to $2.5 million over the next 12 months, reflecting confidence in its stock value.

The repurchase program, authorized by Aclarion's board, is expected to enhance shareholder value and boost market confidence. CEO Brent Ness highlighted that this program is a flexible tool to leverage current share prices while continuing to invest in the clinical adoption and expansion of Nociscan. The company plans to fund the repurchase using existing cash and cash equivalents, ensuring financial stability.

This strategic move is anticipated to not only improve earnings per share but also increase demand for Aclarion's stock, potentially enhancing the company's overall valuation in the competitive healthcare technology market.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy ACON?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on ACON

Wall Street analysts forecast ACON stock price to rise

1 Analyst Rating

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 3.150

Low

23.00

Averages

23.00

High

23.00

Current: 3.150

Low

23.00

Averages

23.00

High

23.00

No data

About ACON

Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Aclarion Responds to Echo Lake's Acquisition Proposal

2 days agoNewsfilter

Acquisition Proposal Response: Aclarion has responded to Echo Lake Capital's acquisition offer of $4.00 per share, stating that the Board will carefully evaluate the proposal to ensure it aligns with the best interests of the company and all shareholders, thereby protecting shareholder value.
Share Repurchase Program: The Board has authorized a share repurchase program, indicating a lack of confidence in the current market valuation, with plans to enhance shareholder value through buybacks while continuing to invest in business development to bolster long-term growth potential.
Board Composition: Aclarion's Board consists of seven highly qualified directors with expertise in healthcare and technology investing, having appointed five new directors in the past six years to ensure diversity and alignment with strategic priorities, thus driving value creation for the company.
Technological Innovation: Aclarion's Nociscan platform leverages Magnetic Resonance Spectroscopy and augmented intelligence algorithms to non-invasively assist physicians in identifying the sources of chronic low back pain, showcasing the company's innovative capabilities and market potential in the healthcare technology sector.

Aclarion Partners with Weill Cornell for Lumbar Surgery Study

May 05 2026NASDAQ.COM

Commercial Agreement Expansion: Aclarion Inc. has established a second commercial agreement with Weill Cornell Medicine to conduct a study on lumbar surgery for degenerative disc disease using its AI-driven platform Nociscan, showcasing the company's ongoing innovation in the healthcare sector.
Technological Advantage: Nociscan combines artificial intelligence with magnetic resonance imaging to non-invasively identify painful discs in the lumbar spine, achieving a 97% success rate, thus providing an effective treatment option for chronic lower back pain affecting approximately 266 million people globally.
Clear Research Objectives: The two-year prospective randomized study led by neurosurgeon Roger Hartl aims to deepen the understanding of degenerative disc disease's natural history, causes, and potential treatments, advancing medical knowledge in this area.
Clinical Application Prospects: The study will evaluate the effectiveness of lumbar microdiscectomy surgery with or without a bone marrow aspirate concentrate injection on patient-reported outcomes, intervertebral disc health, and pain biomarkers, potentially providing crucial data to support future treatment options.

ACLARION SIGNS SECOND COMMERCIAL DEAL WITH WEILL CORNELL MEDICINE

May 05 2026moomoo

Announcement of Agreement: Aclarion has announced a second commercial agreement with Weill Cornell Medicine.
Focus on Collaboration: The agreement aims to enhance collaboration in the field of medical technology and research.

Aclarion Reports 196% Year-over-Year Growth in Nociscan Volumes for Q1 2026

May 01 2026seekingalpha

Significant Volume Growth: Aclarion's Nociscan volumes for Q1 2026 increased by 196% year-over-year compared to Q1 2025, indicating strong market demand and the competitiveness of the company's offerings.
Quarterly Sequential Improvement: The scan volume also grew by 64% sequentially from Q4 2025 to Q1 2026, demonstrating the company's ability to achieve sustained business expansion and customer growth in the short term.
Solid Financial Foundation: As of March 31, 2026, Aclarion reported $19 million in cash with no outstanding debt, providing a robust capital structure that supports ongoing growth initiatives.
Stock Buyback Program: The announcement of a $2.5 million stock buyback program suggests that the company believes its existing cash resources will be sufficient to fund operations into the second half of 2027, thereby enhancing investor confidence and shareholder value.

Aclarion Appoints New Commercial Director to Drive Growth

Apr 28 2026Newsfilter

Team Expansion: Aclarion has appointed Daniel Keefe as Commercial Director for the Western U.S. to drive the adoption of Nociscan, reflecting a surge in market demand, particularly among academic institutions and high-volume private spine centers, supporting the company's continued growth in this key region.
Market Performance: Nociscan has seen triple-digit growth in utilization, underscoring its significance in chronic low back pain management, and is expected to further enhance Aclarion's market share and competitiveness in the healthcare technology sector.
Professional Background: Daniel Keefe brings over 20 years of experience in medical device and technology sales, having held leadership roles at several prominent companies, and his addition is anticipated to provide Aclarion with valuable industry knowledge and market expansion capabilities to bolster business development in the Western U.S.
Technological Advantage: Nociscan is the first evidence-supported cloud platform that noninvasively helps physicians distinguish between painful and non-painful discs, boasting a 97% surgical success rate when treating Nociscan-positive discs, offering new treatment options for chronic low back pain patients.